Lightlake Thera (LLTP) has several technologies and has attracted the interest of several major players in the Pharma/Research arena. The protocol is based on a simple/FDA approved single molecule. This application can be used to commercially treat BED/BULIMIA/NARCOTICS and OPIATE addiction. Once the treatment passes stage two, its risk as an investment decreases dramatically and can be recommended by the brokerage industry based on a successful double blind placebo trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.